Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels

Blood

Volumn 105, Issue 6, 2005, Pages 2571-2576

  Zhou, Sheng ^a   Zong, Yang ^b   Ney, Paul A ^b   Nair, Geeta ^b   Stewart, Clinton F ^b   Sorrentino, Brian P ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINOLEVULINATE SYNTHASE; ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; COPROPORPHYRINOGEN OXIDASE; FERROCHELATASE; PORPHOBILINOGEN DEAMINASE; PROTOPORPHYRIN; PROTOPORPHYRINOGEN OXIDASE; UROPORPHYRINOGEN DECARBOXYLASE; UROPORPHYRINOGEN III SYNTHASE;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; ENZYME ACTIVITY; ENZYME SPECIFICITY; ENZYME SUBSTRATE; ERYTHROID CELL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; INTRAHEPATIC BILE DUCT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY;

EID: 15244352173     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-04-1566     Document Type: Article

References (29)

1. Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 1987;84:7735-7738.
2. Jonker JW, Smit JW, Brinkhuis RF, et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst. 2000;92:1651-1656.
3. Jonker JW, Buitelaar M, Wagenaar E, et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A. 2002;99:15649-15654.
4. Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 2001;61: 3458-3464.
5. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A. 1998;95: 15665-15670.
6. Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res. 1999;59:4237-4241.
7. Knutsen T, Rao VK, Ried T et al. Amplification of 4q21-q22 and the MXR gene in independently derived mitoxantrone-resistant cell lines. Genes Chromosomes Cancer. 2000;27:110-116.
8. Robey RW, Medina-Perez WY, Nishiyama K, et al. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res. 2001;7:145-152.
9. Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 2001;7:1028-1034.
10. Scharenberg CW, Harkey MA, Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood. 2002;99:507-512.
11. Zhou S, Morris JJ, Barnes Y, et al. Bcrp1 gene expression is required for normal numbers of side population stem cells in mice and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci U S A. 2002;99:12339-12344.
12. Goodell MA, Rosenzweig M, Kim H, et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med. 1997;3:1337-1345.
13. Zhou S, Zong Y, Lu T, Sorrentino BP. Hematopoietic cells from mice that are deficient in both Bcrp1/Abcg2 and Mdr1a/1b develop normally but are sensitized to mitoxantrone. Biotechniques. 2003;35:1248-1252.
14. Abbott BL, Colapietro AM, Barnes Y, et al. Low levels of ABCG2 expression in adult AML blast samples. Blood. 2002;100:4594-4601.
15. Koury MJ, Sawyer ST, Bondurant MC. Splenic erythroblasts in anemia-inducing Friend disease: a source of cells for studies of erythropoietin-mediated differentiation. J Cell Physiol. 1984;121: 526-532.
16. Kina T, Ikuta K, Takayama E, et al. The monoclonal antibody TER-119 recognizes a molecule associated with glycophorin A and specifically marks the late stages of murine erythroid lineage. Br J Haematol. 2000;109:280-287.
17. Allen JD, van Loevezijn A, Lakhai JM, et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther. 2002;1:417-425.
18. Ferreira GC, Andrew TL, Karr SW, Dailey HA. Organization of the terminal two enzymes of the heme biosynthetic pathway: orientation of protoporphyrinogen oxidase and evidence for a membrane complex. J Biol Chem. 1988;263:3835-3839.
19. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003;3:380-387.
20. Gederaas OA, Berg K, Romslo I. A comparative study of normal and reverse phase high pressure liquid chromatography for analysis of porphyrins accumulated after 5-aminolaevulinic acid treatment of colon adenocarcinoma cells. Cancer Lett. 2000;150:205-213.
21. Shirihai OS, Gregory T, Yu C, Orkin SH, Weiss MJ. ABC-me: a novel mitochondrial transporter induced by GATA-1 during erythroid differentiation. EMBO J. 2000;19:2492-2502.
22. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001;11:1156-1166.
23. Gottesman MM, Ambudkar SV. Overview: ABC transporters and human disease. J Bioenerg Biomembr. 2001;33:453-458.
24. Tutois S, Montagutelli X, Da Silva V, et al. Erythropoietic protoporphyria in the house mouse: a recessive inherited ferrochelatase deficiency with anemia, photosensitivity, and liver disease. J Clin Invest. 1991;88:1730-1736.
25. Magness ST, Maeda N, Brenner DA. An exon 10 deletion in the mouse ferrochelatase gene has a dominant-negative effect and causes mild protoporphyria. Blood. 2002;100:1470-1477.
26. DeLeo VA, Poh-Fitzpatrick M, Mathews-Roth M, Harber LC. Erythropoietic protoporphyria: 10 years' experience. Am J Med. 1976;60:8-22.
27. Went LN, Klasen EC. Genetic aspects of erythropoietic protoporphyria. Ann Hum Genet. 1984;48:105-117.
28. Lamoril J, Boulechfar S, de Verneuil H, et al. Human erythropoietic protoporphyria: two point mutations in the ferrochelatase gene. Biochem Biophys Res Commun. 1991;181:594-599.
29. Zamber CP, Lamba JK, Yasuda K, et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics. 2003;13:19-28.